Skip to main content
. 2021 Nov 22;11:742354. doi: 10.3389/fonc.2021.742354

Table 2.

Correlations between preoperative AFU levels and clinicopathological parameters of PCa patients.

Characteristics N (%) AFU levels (U/L, mean ± SD) p-Value
Patientsa 196 (100%) 16.35 ± 5.20
Age 0.144*
<69 92 (46.9%) 16.92 ± 5.87
≥69 104 (53.1%) 15.59 ± 4.29
PSA (ng/ml) 0.043 *
<4 49 (25%) 17.63 ± 5.41
≥4 116 (59.2%) 15.89 ± 5.01
Missing data 31 (15.8%)
LDHa 0.585*
<197 102 (52.0%) 16.47 ± 5.42
≥197 80 (40.8%) 16.41 ± 4.60
Missing data 14 (7.1%)
SAa 0.954*
<56 110 (56.1%) 16.38 ± 4.83
≥56 71 (36.2%) 16.62 ± 5.44
Missing data 15 (7.7%)
AKPa 0.364*
<75 114 (58.2%) 16.34 ± 5.58
≥75 71 (36.2%) 16.42 ± 4.11
Missing data 11 (5.6%)
Pathological grade group
Low-grade group (<8) 107 (54.6%) 16.45 ± 5.31 0.531*
High-grade group (≥8) 89 (45.4%) 15.93 ± 4.90
T stage 0.050 *
T1 and T2 141 (71.9%) 16.73 ± 5.32
T3 and T4 55 (28.1%) 14.89 ± 4.35
N stage 0.017 *
N0 185 (94.4%) 16.41 ± 5.13
N1 11 (5.6%) 12.91 ± 3.81
Bone metastasis 0.105a *
No 99 (50.5%) 16.74 ± 5.36 0.924b *
Yes 14 (7.1%) 14.21 ± 4.14
Suspicion 23 (11.7%) 16.30 ± 4.70
Missing data 60 (30.6%)

Pathological grade falls into high grade and low grade using the GS. Pathological stage is assessed by postoperative pathology results (not biopsy) in accordance with 2002 TNM classification; p < 0.05 is considered as statistically significant.

PCa, prostate cancer; BPH, benign prostate hyperplasia; AFU, alpha-l-fucosidase; PSA, prostate-specific antigen; LDH, lactate dehydrogenase; SA, serum sialic acid; AKP, alkaline phosphatase; GS, Gleason system.

aContinuous variables are expressed as median.

ap: no bone metastases versus bone metastases.

bp: no bone metastases versus suspicion.

*p: Mann–Whitney U-test.

Bold values was used for emphasis, means p ≤ 0.05.